New Product & Service Launches, Collaborations and Quarterly Earnings Schedules - Research Report on Valeant, Lilly, Dr. Reddy's, Celgene and Vertex
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, July 11, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX), Eli Lily & Co. (NYSE: LLY), Dr. Reddy's Laboratories Limited (NYSE: RDY), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Valeant Pharmaceuticals Intl. Inc. Research Report
On July 2, 2013, Medicis, a division of Valeant Pharmaceuticals International, Inc. (Valeant), announced a collaboration with Mentor Worldwide LLC, to enter certain of their non-reimbursed products into a combined physician loyalty program called M2VP (Medicis-Mentor Valued Partner). M2VP extends the offerings of Medicis' recently-launched MVP program to include the MENTOR line of breast implant products for a five-year term, and offers numerous incentives that reward the use of various products across the Mentor and Medicis portfolios. The program allows participating members not only to earn points but to redeem them for items such as product purchases. "With this program we are providing our customers with opportunities for volume-based cost savings on the products they use and added incentives to try other products from our combined portfolios," said Ryan Weldon, President of Medicis. "We believe that the M2VP program is one of the most comprehensive loyalty programs in the industry and will bring value to all practices, both large and small. The addition of Mentor's breast aesthetic portfolio is truly exciting news for our customers and we are excited about future iterations of the program to come." The Full Research Report on Valeant Pharmaceuticals Intl. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/94d5_VRX]
--
Eli Lily & Co. Research Report
On July 8, 2013, Eli Lilly & Co. (Lilly) announced the return of John C. Lechleiter, Ph. D., as Lilly's Chairman, President and CEO. Lechleiter had been on medical leave since his scheduled surgery for a dilated aorta on May 13, 2013. "I am overwhelmed and humbled by the tremendous support and well-wishes I have received from my friends and fellow Lilly colleagues around the world," Lechleiter said. "I return to Lilly with renewed energy and enthusiasm, along with a new perspective on health and wellness and the critical importance of new medicines in advancing patient care." Lechleiter's surgery and recovery were successful and he has been cleared by his personal physician and the Company's employee health services physician to return to full-time work. Lilly EVP Derica Rice served as acting CEO during Lechleiter's leave. The Full Research Report on Eli Lily & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/937b_LLY]
--
Dr. Reddy's Laboratories Limited Research Report
On June 26, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) announced the launch of Lamotrigine Extended-Release Tablets (in 25, 50, 100, 200 and 300 mg), a therapeutic equivalent generic version of Lamictal XR (lamotrgine) in the US market on June 25, 2013, following US FDA approval of the Company's ANDA for Lamotrigine XR tablets. According to IMS Health, the Lamictal XR brand and generic had combined U.S. sales of approximately $300.5 million MAT for the most recent twelve months ending in April 2013. The Full Research Report on Dr. Reddy's Laboratories Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e286_RDY]
--
Celgene Corporation Research Report
On July 8, 2013, Celgene Corporation (Celgene) will discuss its Q2 2013 financial results via a conference call and live audio webcast on Thursday, July 25, 2013 at 9:00 a.m. ET. The webcast can be accessed at the Company's website. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/7541_CELG]
--
Vertex Pharmaceuticals Incorporated Research Report
On June 27, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced it will report its Q2 2013 financial results on Monday, July 29, 2013 after the market close via a conference call and webcast at 5:00 p.m. ET. The conference call will be webcast live and a link to the webcast may be accessed from the "Vertex Events" page of Vertex's website. A replay of the conference call and webcast will be archived on the company's website until August 5, 2013. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/ec92_VRTX]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article